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Penefit With Impella?
e are concerned about the report from the Europella registry (1),
hich described the use of the Impella 2.5 device (ABIOMED
nc., Danvers, Massachusetts) in 144 European patients undergo-
ng elective high-risk coronary intervention. If this device or any
ther has merit in an elective, high-risk population, it must
roduce fewer adverse events than would be expected without the
evice.
Most patients had multivessel disease; left main disease (LMD)
as listed as a high-risk criterion for more than one-half of the
atients. Reported 30-day mortality figures were 5.5% overall, with
urprisingly little variation as a function of left ventricular ejection
raction. Mortality rates were much higher among LMD patients:
.3% overall, and 12% for those with LMD and low left ventricular
jection fraction.
The mean EuroSCORE (European System for Cardiac Oper-
tive Risk Evaluation) of about 8 suggests a 30-day mortality risk
f about 5% with unsupported percutaneous coronary intervention
2). The investigators note that in the SYNTAX (Synergy between
ercutaneous Coronary Intervention with Taxus and Cardiac
urgery) trial (3), 12-month mortality was 7.3% for patients who
efused bypass surgery, but the 30-day risk for such patients was
ot reported in SYNTAX, and surgical turn-down was cited as a
igh-risk feature in fewer than one-half of the patients in the
mpella registry. Overall 12-month mortality in SYNTAX was
.3%, and for LMD patients it was 4.2%, which is roughly
ne-half the 30-day mortality for LMD patients treated with
mpella in this registry. This is of concern as an overall mortality
isk that matches or exceeds the risk predicted without special
upport and questions the magnitude of benefit achieved through
se of Impella. Ease of use is an attractive feature of the Impella
evice, but ease should not drive its use in the absence of
emonstrated efficacy. We anxiously await the completion of
ROTECT II (A Prospective Multicenter, Randomized Con-
rolled Trial of the Impella Recover LP 2.5 System versus
ntra-Aortic Balloon Pump in Patients Undergoing Nonemergent
igh-Risk PCI) trial, which will clarify possible benefits of this
ntermediate support device in elective high-risk percutaneous
oronary intervention.
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eply
e thank Drs. Garratt and Holmes for their interest in our report
1), and we could not agree more with their statement that the
mpella 2.5 or any other mechanical cardiac-assist device only has
erit in the setting of elective high-risk percutaneous coronary
ntervention (PCI) if there are more benefits than iatrogenic
dverse events to expect. However, we do not agree with the raised
oncerns with regard to the 30-day mortality rate of 5.5% in the
uropella registry (1).
Drs. Garratt and Holmes state that an overall mortality risk that
atches or exceeds the risk predicted without special support
uestions the magnitude of benefit achieved through use of
mpella. However, the mortality rates mentioned by Drs. Garratt
nd Holmes are far from comparable with the mortality rate
eported in the Europella registry. First, the deduction from the
ited study of Romagnoli et al. (2) that a EuroSCORE (European
ystem for Cardiac Operative Risk Evaluation) of 8 corresponds
ith a 30-day mortality risk of about 5% in unsupported elective
CI is invalid. This single-center study only shows that the
uroSCORE has good discriminative power to predict mortality
n the included cohort of PCI patients. Only if both studies had
ncluded approximately similar patients, a crude comparison of
ortality rates would have been reasonable. However, the case mix
f patients in the study of Romagnoli et al. (2) was completely
ifferent than the Europella registry (e.g., both emergent and
lective patients; lower age; considerably lower frequencies of
iabetes, hypertension, renal failure, peripheral vascular disease,
nd stroke; normal left ventricular ejection fraction in 75% of
atients; and only 2.3% had left main disease). Moreover, due to
ack of angiographic parameters of coronary anatomy, patients
ith identical “surgical” EuroSCOREs may have completely
ifferent mortality rates.
The Europella registry included a selected group of high-risk
atients from multiple centers with high morbidity, poor left
entricular ejection fraction, and complex 3-vessel and left main
isease seldom included in previous trials. Therefore, as part of the
real-world” design of the SYNTAX (Synergy between Percuta-
eous Coronary Intervention with Taxus and Cardiac Surgery)
rial (3) (eligibility for coronary artery bypass graft [CABG] or
CI judged in the “Heart-Team Conference”), the SYNTAX
egistry for CABG ineligible patients in our opinion included the
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June 8, 2010:2608–13ost comparable patient population; indeed, only 43% of the
atients were formally refused for CABG in the Europella registry,
ut all were judged poor candidates for CABG and conventional
“unsupported”) PCI. It is true that only a 12-month mortality rate
s reported in the SYNTAX registry, but as mentioned, better
omparable figures are lacking.
Finally, it must be clear that the case mix included in the
YNTAX trial (all patients equally eligible for CABG and PCI,
eft ventricular ejection fraction 30% only in 1.3% of patients,
ower comorbidity profile, mean EuroSCORE of 3.8) differs too
uch from the Europella registry for a valid comparison of
ortality rates.
In conclusion, we think that the mortality rate of 5.5% is within
he expected mortality range for this high-risk patient group,
hich a priori were at high risk for mortality and prone for
eriprocedural complications due to its high comorbidity and
xtensive coronary artery disease profile. Use of Impella resulted in
high procedural success rate with a relatively low periprocedural
omplication rate. Notwithstanding, we also eagerly await the
esults of the randomized PROTECT II (A Prospective Multi-
enter, Randomized Controlled Trial of the Impella Recover LP
.5 System versus Intra-Aortic Balloon Pump in Patients Under-
oing Nonemergent High-Risk PCI) trial.
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cademic Medical Center–University of Amsterdam
eibergdreef 9
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arning on Diuretic Use
ainchbury et al. (1) compared the effect of treatment guided by
-terminal pro-B-type natriuretic peptide with intensive clinical
anagement and usual care among 364 patients with chronic heart
ailure (1). They concluded that intensive management of chronic
eart failure, when compared with usual care, improves 1-year
ortality. Although there was a modest increase in the doses of
eta-blockers, the major difference between the hospital groups
as adjustment of the dose of furosemide. One could therefore beeft with the impression that the proper treatment of such patients
hould be an increase in the dose of diuretics. However, this
onclusion is based on a low number of events. The overall
umbers of deaths (according to Table 4 of Lainchbury et al. [1])
ere 7, 6, and 16 in the first year in the N-terminal pro-B-type
atriuretic peptide, intensive clinical management, and usual care
roups, respectively, and one could therefore not exclude that the
ndings were due to chance. Lainchbury et al. (1) also needed to
xplain their other conclusion that hormone-guided treatment
electively improves long-term mortality in patients 75 years of
ge, because (according to Table 4 of Lainchbury et al. [1]) the
umbers of deaths during 3 years were 6, 6, and 12, respectively.
What is more worrisome is the background therapy on which
hese results are based. The proportion of patients using
ngiotensin-converting enzyme inhibitors (ACEIs)/angiotensin
eceptor blockers (ARBs), beta-blockers, and spironolactone were
7% to 84%, 65% to 71%, and 12% to 17%, respectively, and the
oses of ACEIs/ARBs and beta-blockers were approximately 60%
nd 40% of recommended doses. In comparison, in the Norwegian
eart Failure Registry among 3,632 patients, mean age 71 years,
he proportion of patients using ACEIs/ARBs, beta-blockers, and
pironolactone were 87%, 83%, and 27%, respectively, whereas the
oses of ACEIs and beta-blockers were 80% and 58% of recom-
ended target doses, respectively. Contrary to the present study
here the dose of furosemide increased to nearly 200 mg/day, we
ere able to reduce the dose from 58 to 53 mg/day during
ptimization of drug treatment in our population of patients with
ne-half of the patients in New York Heart Association functional
lasses III to IV at baseline (2). Moreover, we found the daily dose
f diuretics to be an independent predictor of mortality (3). In fact,
t was the strongest predictor of mortality adjusted for age,
stimated glomerular filtration rate, New York Heart Association
unctional class, hemoglobin, serum sodium concentration, stroke,
nd ischemic heart disease. A large number of other variables were
ot significantly related.
Until it is better documented that the hormone-assisted treat-
ent is better than clinical care, doctors should be cautious to
p-titrate the diuretic dose on the basis of this blood test. Because
t is now well documented that both the proportion and dosing of
CEIs/ARBs and beta-blockers have an impact on mortality and
orbidity, such recommendations should at least be based on
rospective, randomized studies where the patients are optimally
reated from the start.
Morten Grundtvig, MD, BSc
rne Westheim, MD, PhD
orstein Hole, MD, PhD
erit Flønæs, RN
ars Gullestad, MD, PhD
n behalf of the Norwegian Heart Failure Registry
Innlandet Hospital Trust
edical Department
. Sandvigsgt 17
-2629 Lillehammer
orway
-mail: mgrundtv@online.nodoi:10.1016/j.jacc.2010.02.039
